IDiyas

For the Inventor, By the Inventor

Bethesda, MD, United States of America

Lewis Markoff

USPTO Granted Patents = 9


 

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 62(Granted Patents)


Company Filing History:

goldMedal9 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents

Years Active: 2004-2023

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 11753627 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2023-09-12),
2. 10837003 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 (2020-11-17),
3. RE46641 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2017-12-18),
4. RE46631 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2017-12-11),
5. 9783787 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 (2017-10-10),
6. 8075903 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4 (2011-12-13),
7. 7851194 - West Nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines (2010-12-14),
8. 7517531 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 (2009-04-14),
9. 6685948 - Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines (2004-02-03),

Title: Lewis Markoff: Pioneer in Dengue Vaccine Innovation

Introduction

Lewis Markoff, located in Bethesda, MD, is a prominent inventor renowned for his significant contributions in the field of vaccine development. With a total of nine patents to his name, Markoff has been at the forefront of innovations aimed at combating infectious diseases, particularly dengue fever.

Latest Patents

Markoff's latest inventions focus on developing a dengue tetravalent vaccine. This vaccine contains a common 30 nucleotide deletion in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of the same serotypes. This breakthrough has the potential to enhance the efficacy and safety of dengue vaccinations, addressing a pressing public health need.

Career Highlights

Markoff’s career is marked by his dedication to improving public health through innovative vaccine research. His association with the Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, showcases his commitment to advancing medical science and combating global health threats.

Collaborations

Throughout his career, Markoff has collaborated with esteemed colleagues such as Stephen S. Whitehead and Brian R. Murphy. These collaborations have further enriched his research and contributed to the successful patents and innovations in his portfolio.

Conclusion

Lewis Markoff’s work exemplifies the vital role of inventors in public health. Through his innovative approaches to dengue vaccine development, he continues to make significant strides in the fight against infectious diseases, demonstrating the impact that dedicated inventors can have on society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…